The efficacy of sirolimus in the treatment of patients with refractory uveitis
about
Emerging drugs for uveitisMedical management of uveitis - current trendsPharmacotherapy for uveitis: current management and emerging therapy.Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.The role of anti-inflammatory agents in age-related macular degeneration (AMD) treatmentReview of Systemic Immunosuppression for Autoimmune UveitisA retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis.Subconjunctival sirolimus in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trialSurface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.Tacrolimus immunosuppression in high-risk corneal grafts.Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells.Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial.In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device.Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE StudyTreatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Pharmacotherapy of uveitis.Road to remission: a comprehensive review of therapy in uveitis.Systemic treatment of vitreous inflammation.Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.Systemic treatments for noninfectious vitreous inflammation.Emerging therapies for noninfectious uveitis: what may be coming to the clinicsNew pharmacotherapy options for noninfectious posterior uveitis.Small molecules as therapy for uveitis: a selected perspective of new and developing agents.Current advances in the treatment of neovascular age-related macular degeneration.Sirolimus for the treatment of noninfectious uveitis.The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis).Ciclosporin use in dry eye disease patients
P2860
Q24630848-794A895F-2002-4D6F-BB07-89C83342F29EQ27003399-5933722B-B7A6-4F6C-9770-6B246D8A7815Q34274075-B69F0818-BC67-4554-9299-47F522931C18Q34449084-A8F3F451-43E6-4082-A4AE-30044C79D9C2Q34530196-86D6E148-B3A5-4878-A779-13F30701F88FQ34605896-6F9186E8-9816-45C9-BBCF-9C312623EAF9Q34627012-9A9899A5-5046-4E15-80E4-4C1771045DC8Q34709640-F8CE227E-8FD0-4D00-9B33-B7AAF04B2935Q35085846-06E07244-8566-4D82-8014-17CF6B64B0B3Q35087664-FA0DF103-2EFF-4B40-952F-17006B479E57Q35762878-1782EF0B-036B-474A-B55C-231CBCE56181Q35964539-4C6A23DC-4C28-43ED-B06A-33600597E346Q35981222-5107EB1C-30EF-4983-A0D7-8562C2B4EF52Q36273801-39A0DE5E-F1BA-4C10-866E-E497A23A6B75Q36722548-A3088432-9949-4732-AE70-265F024D15C4Q36801990-AE7300C7-104B-4888-AC1F-4E09803645D8Q37724245-C62EA47E-2B24-4D31-B130-F5B2889C43EBQ37936459-85766C8A-8766-4C27-AF13-2179C024BBBBQ38048774-7D0CF8F7-1F9C-4E22-A04F-CE139427C4A0Q38069093-E3F6A8F4-5C70-4933-B102-BC20918E5043Q38172090-07AD54A7-AF7F-4119-A660-053EEC2A3923Q38215514-32E76442-0A05-4167-AF13-E39C61483A62Q38253095-B2255564-BE84-47D1-AAE6-ABE45FE55097Q38650868-66D72DE0-0BF8-4E34-9F95-EEB992324415Q38902191-E7230B24-6E31-4CC0-AAC3-BBAFE6819960Q38938749-499CEF61-0F4C-484A-A4B5-CB08DEE75AE4Q40539739-25A2CE8C-6E3A-4AC6-98AB-ECE4436AFF98Q56864480-5FCFBDF9-CA80-480B-AE64-4141375AFD53
P2860
The efficacy of sirolimus in the treatment of patients with refractory uveitis
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@ast
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@en
type
label
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@ast
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@en
prefLabel
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@ast
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@en
P2093
P2860
P356
P1476
The efficacy of sirolimus in the treatment of patients with refractory uveitis
@en
P2093
E M Casely
R J Powell
V A Shanmuganathan
W M Amoaku
P2860
P304
P356
10.1136/BJO.2004.048199
P407
P577
2005-06-01T00:00:00Z